All studies
RecruitingPHASE3INTERVENTIONAL
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
At a glance
Status
Recruiting
Phase
PHASE3
Sponsor
Amgen
Enrolment target
12,800
Start
25 Jul 2025
Estimated completion
29 Sep 2030
What is this study about?
The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
Who may be eligible?
Age 45 Years to 99 Years · Sex: ALL
Locations (772)
- Alliance For Multispecialty Research - DaphneDaphne, United States· Recruiting
- Eastern Shore Research InstituteFairhope, United States· Recruiting
- Heart Center Research LLCHuntsville, United States· Recruiting
- Mobile Heart Specialists PCMobile, United States· Recruiting
- Syed Research Consultants LLCSheffield, United States· Recruiting
- Synexus Clinical Research US, Inc.Phoenix, United States· Recruiting
- Medical Advancement Centers of ArizonaPhoenix, United States· Recruiting
- Valley Clinical Trials, LLC dba Flourish ResearchCovina, United States· Recruiting
- Velocity Clinical Research- Huntington ParkHuntington Park, United States· Recruiting
- Velocity Clinical Research- Los AngelesLa Mesa, United States· Completed
- Orange County Research CenterLake Forest, United States· Recruiting
- Biopharma Informatic - The Cardiovascular CenterRedding, United States· Recruiting
+760 more sites — see the official record for the full list.
How to find out more
Amgen Call Center
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.